PACT.ST
Proact IT Group AB (publ)
StockholmSEKEQUITY
Technology
DELAYED
Last price
125.60
▲ 1.20 (0.96%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
124.60
Prev close
124.40
Day high
126.40
Day low
123.20
Volume
47.37K
Market cap
$3.17B
P/E (TTM)
16.72
52W range
88.00 – 145.40
Day trading desk
Gap from prior close
+0.16%
Prior close 124.40
VWAP
125.36
+0.19% from price
Relative volume
1.32×
Normal
Session range
2.60%
123.20 – 126.40
Position in range
75%
Near session high
ATR (14D)
2.46
1.96% of price
Prior day high
125.60
PDH
Prior day low
123.00
PDL
Bid / ask spread
—
Quote not published
Session volume
70.83K
Avg 53.65K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.29%
+2.4%
1M
+4.67%
+1.3%
3M
-6.69%
-9.1%
6M
+23.62%
+11.7%
YTD
+10.95%
-1.0%
1Y
+33.90%
+13.7%
3Y
+72.29%
-2.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on PACT.ST open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.85M
Total on file
Fundamentals
Market cap$3.17B
Enterprise value$3.27B
Revenue (TTM)$4.82B
Gross profit$1.16B
EBITDA$401.22M
Net income$190.75M
EPS (TTM)$7.51
Free cash flow$361.64M
Total cash$475.00M
Total debt$600.00M
Book value / share$43.32
Shares outstanding25.26M
Float20.08M
Short % of float—
Dividend yield2.09%
Beta (5Y)0.91
Valuation & profitability ratios
Trailing P/E16.72
Forward P/E14.19
PEG ratio1.23
Price / sales—
Price / book2.90
EV / revenue0.68
EV / EBITDA8.14
Gross margin24.00%
Operating margin6.93%
Profit margin3.96%
Return on equity17.30%
Return on assets4.42%
Debt / equity54.85
Current ratio1.01
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $4.68B | $4.86B | $4.85B | $4.76B | -3.8% |
| Operating revenue | $4.68B | $4.86B | $4.85B | $4.76B | -3.8% |
| Cost of revenue | $3.57B | $3.66B | $3.76B | $3.70B | -2.3% |
| Gross profit | $1.11B | $1.21B | $1.09B | $1.05B | -8.4% |
| Selling, general & admin | $851.68M | $912.97M | $859.44M | $792.07M | -6.7% |
| Total operating expense | $851.68M | $912.97M | $859.44M | $792.07M | -6.7% |
| Operating income | $255.06M | $295.54M | $229.75M | $260.60M | -13.7% |
| Net interest income | -$15.77M | -$15.89M | -$9.73M | -$15.98M | +0.8% |
| Pre-tax income | $137.68M | $277.95M | $218.27M | $244.15M | -50.5% |
| Tax provision | $14.93M | $58.08M | $45.18M | $52.61M | -74.3% |
| Net income | $122.75M | $219.88M | $172.65M | $191.26M | -44.2% |
| Net income to common | $122.75M | $219.88M | $172.65M | $191.26M | -44.2% |
| Basic EPS | 4.67 | 8.15 | 6.29 | 6.97 | -42.7% |
| Diluted EPS | 4.67 | 8.15 | 6.29 | 6.97 | -42.7% |
| EBIT | $148.71M | $306.41M | $247.79M | $264.28M | -51.5% |
| EBITDA | $360.82M | $520.49M | $476.00M | $476.86M | -30.7% |
| Basic shares | 26.28M | 26.99M | 27.47M | 27.45M | -2.6% |
| Diluted shares | 26.28M | 26.99M | 27.47M | 27.45M | -2.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $458.01M | $813.52M | $547.90M | $505.68M | -43.7% |
| Cash & short-term investments | $458.01M | $813.52M | $547.90M | $505.68M | -43.7% |
| Accounts receivable | $703.52M | $756.38M | $717.66M | $849.78M | -7.0% |
| Inventory | $23.59M | $20.84M | $15.44M | $64.06M | +13.2% |
| Total current assets | $1.95B | $2.37B | $2.00B | $2.09B | -17.8% |
| Property, plant & equipment | $327.02M | $319.17M | $319.32M | $366.85M | +2.5% |
| Goodwill & intangibles | $1.47B | $1.15B | $1.16B | $1.21B | +27.9% |
| Total assets | $4.42B | $4.48B | $4.04B | $4.24B | -1.3% |
| Total current liabilities | $2.19B | $1.92B | $1.83B | $1.88B | +14.1% |
| Current debt | $216.36M | $0 | $0 | $0 | — |
| Long-term debt | $0 | $229.73M | $221.92M | $440.67M | -100.0% |
| Total debt | $478.61M | $483.46M | $468.27M | $731.24M | -1.0% |
| Total liabilities | $3.38B | $3.30B | $3.04B | $3.32B | +2.2% |
| Retained earnings | $695.98M | $760.40M | $632.42M | $538.99M | -8.5% |
| Shareholder equity | $1.04B | $1.17B | $1.01B | $919.53M | -11.1% |
| Working capital | -$239.01M | $451.82M | $162.84M | $209.79M | -152.9% |
| Net tangible assets | -$430.69M | $21.10M | -$152.28M | -$294.83M | -2,141.3% |
| Shares issued | 27.10M | 27.40M | 28.00M | 28.00M | -1.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $171.05M | $295.54M | $229.75M | $260.60M | -42.1% |
| Depreciation & amortisation | $212.11M | $214.08M | $228.21M | $212.58M | -0.9% |
| Change in working capital | $38.68M | $43.70M | $105.00M | -$20.47M | -11.5% |
| Operating cash flow | $383.16M | $524.07M | $532.04M | $454.26M | -26.9% |
| Capital expenditure | -$42.38M | -$31.23M | -$45.31M | -$41.01M | -35.7% |
| Investing cash flow | -$337.49M | -$26.51M | -$51.93M | -$194.62M | -1,172.9% |
| Share buybacks | -$118.36M | -$42.80M | -$19.59M | $0 | -176.5% |
| Dividends paid | -$64.25M | -$53.98M | -$50.79M | -$41.18M | -19.0% |
| Financing cash flow | -$365.46M | -$247.15M | -$430.06M | -$247.39M | -47.9% |
| Free cash flow | $340.78M | $492.85M | $486.73M | $413.25M | -30.9% |
| End cash position | $458.01M | $813.52M | $547.90M | $505.68M | -43.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $1.29B | $1.24B | $1.21B | $1.17B | $1.22B | +3.5% |
| Operating revenue | $1.29B | $1.24B | $1.21B | $1.17B | $1.22B | +3.5% |
| Cost of revenue | $985.00M | $929.00M | $924.80M | $899.00M | $926.00M | +6.0% |
| Gross profit | $301.00M | $314.00M | $283.30M | $274.00M | $289.00M | -4.1% |
| Selling, general & admin | $212.00M | $214.00M | $217.30M | $215.00M | $223.00M | -0.9% |
| Total operating expense | $212.00M | $214.00M | $217.30M | $215.00M | $223.00M | -0.9% |
| Operating income | $89.00M | $100.00M | $66.00M | $59.00M | $66.00M | -11.0% |
| Net interest income | -$4.00M | -$6.00M | -$5.10M | -$7.00M | -$2.00M | +33.3% |
| Pre-tax income | $86.00M | $95.00M | $5.70M | $26.00M | $61.00M | -9.5% |
| Tax provision | $23.00M | $17.00M | -$8.70M | $3.00M | $13.00M | +35.3% |
| Net income | $62.00M | $78.00M | $14.40M | $24.00M | $48.00M | -20.5% |
| Net income to common | $62.00M | $78.00M | $14.40M | $24.00M | $48.00M | -20.5% |
| Basic EPS | 2.47 | 3.04 | 0.56 | 0.89 | 1.79 | -18.7% |
| Diluted EPS | 2.47 | 3.04 | 0.56 | 0.89 | 1.79 | -18.7% |
| EBIT | $89.00M | $100.00M | $66.00M | $59.00M | $66.00M | -11.0% |
| EBITDA | $141.00M | $150.00M | $125.30M | $116.00M | $113.00M | -6.0% |
| Basic shares | 25.26M | 25.55M | 25.93M | 26.72M | 26.86M | -1.2% |
| Diluted shares | 25.26M | 25.55M | 25.93M | 26.72M | 26.86M | -1.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $475.00M | $499.00M | $458.01M | $571.40M | $568.40M | — | -4.8% |
| Cash & short-term investments | $475.00M | $499.00M | $458.01M | $571.40M | $568.40M | — | -4.8% |
| Accounts receivable | $1.54B | $1.66B | $703.52M | $1.43B | $1.37B | — | -7.2% |
| Inventory | $41.00M | $53.00M | $23.59M | $25.20M | $21.80M | — | -22.6% |
| Total current assets | $2.06B | $2.21B | $1.95B | $2.02B | $1.96B | — | -7.0% |
| Property, plant & equipment | $329.00M | $327.00M | $327.02M | $318.60M | $318.90M | — | +0.6% |
| Goodwill & intangibles | $1.49B | $1.48B | $1.47B | $1.42B | $1.42B | — | +0.8% |
| Total assets | $4.61B | $4.73B | $4.42B | $4.42B | $4.32B | — | -2.5% |
| Total current liabilities | $2.03B | $2.19B | $2.19B | $1.93B | $1.81B | — | -7.2% |
| Current debt | $182.00M | $96.00M | $216.36M | $197.60M | $198.70M | — | +89.6% |
| Long-term debt | $418.00M | $382.00M | $0 | $423.40M | $418.10M | — | +9.4% |
| Total debt | $600.00M | $478.00M | $478.61M | $621.00M | $616.80M | — | +25.5% |
| Total liabilities | $3.52B | $3.65B | $3.38B | $3.31B | $3.16B | — | -3.6% |
| Retained earnings | $716.00M | — | $695.98M | — | — | $760.40M | — |
| Shareholder equity | $1.09B | $1.08B | $1.04B | $1.11B | $1.16B | — | +1.3% |
| Working capital | $25.00M | $22.00M | -$239.01M | $95.30M | $147.20M | — | +13.6% |
| Net tangible assets | -$394.00M | -$396.00M | -$430.69M | -$312.30M | -$260.40M | — | +0.5% |
| Shares issued | 25.65M | 27.10M | 27.10M | 26.67M | 27.40M | — | -5.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $90.00M | $101.00M | $10.80M | $33.00M | $62.00M | -10.9% |
| Depreciation & amortisation | $52.00M | $50.00M | $59.30M | $57.00M | $47.00M | +4.0% |
| Change in working capital | -$13.00M | $19.00M | $153.40M | $80.00M | -$58.00M | -168.4% |
| Operating cash flow | $107.00M | $144.00M | $229.10M | $127.00M | $55.00M | -25.7% |
| Capital expenditure | -$3.00M | -$7.00M | -$7.10M | -$18.00M | -$10.00M | +57.1% |
| Investing cash flow | $4.00M | -$20.00M | -$96.30M | -$26.00M | -$215.00M | +120.0% |
| Share buybacks | $0 | -$52.00M | — | -$19.00M | -$13.00M | +100.0% |
| Dividends paid | -$66.00M | — | — | -$64.00M | — | — |
| Financing cash flow | -$140.00M | -$94.00M | -$108.70M | -$105.00M | -$58.00M | -48.9% |
| Free cash flow | $104.00M | $137.00M | $222.00M | $109.00M | $45.00M | -24.1% |
| End cash position | $475.00M | $499.00M | $458.00M | $571.00M | $568.00M | -4.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 2.39 | 2.47 | +3.4% |
| Mar 2026 | 1.94 | 3.04 | +56.7% |
| Dec 2025 | 1.52 | 0.56 | -63.2% |
| Sep 2025 | 1.29 | 1.39 | +7.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 2.48 | 2 | $1.22B | +12.6% |
| Next quarter | 2.10 | 2 | $1.26B | +4.0% |
| Current year | 11.93 | 2 | $5.00B | +7.0% |
| Next year | 11.47 | 2 | $5.03B | +0.4% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy0 / 0
Hold0
Sell / Strong sell0 / 0
Held by insiders15.23%
Held by institutions52.91%
Institutions holding43
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
124.50
+0.88% from price
SMA 20
124.74
+0.69% from price
SMA 50
125.09
+0.41% from price
SMA 100
123.70
+1.54% from price
SMA 200
113.97
+10.20% from price
EMA 12
124.53
+0.86% from price
EMA 26
124.64
+0.77% from price
EMA 50
124.71
+0.71% from price
RSI (14)
53.5
Neutral
MACD (12,26,9)
-0.11
Hist 0.07
ATR (14)
2.46
1.96% of price
Realised vol 30D
24.3%
Annualised
Bollinger upper
126.87
20, 2σ
Bollinger lower
122.61
20, 2σ
50 / 200 cross
Golden
125.09 vs 113.97
Trend bias
Above 200
+10.20%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.22
Less volatile than market
Correlation to SPY
0.09
Largely independent
Realised vol 30D
24.3%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-17.1%
Peak to trough
Max drawdown 5Y
-46.0%
Peak to trough
ATR 14
2.46
1.96% of price
Beta (reported)
0.91
5Y monthly, from filing
Dividends & splits
Forward rate$2.60 / yr
Forward yield2.09%
5-year avg yield1.93%
Payout ratio34.62%
Ex-dividend dateMay 6, 2026
Next pay date—
Last split3:1
Split dateMay 19, 2021
Headlines
United Vein & Vascular Centers Expands Tampa Bay Network With New South Tampa Vein Clinic
PR Newswire · 6m ago
In HelloNation, Insurance Expert Brandon D. Allen Discusses What Matters When Choosing an Insurance Agent
PR Newswire · 7m ago
3 High-Flying Stocks We Find Risky
StockStory · 7m ago
Cycle Pharmaceuticals launches CAVHANZA™ (nilotinib) Orally Disintegrating Tablets (ODT), designed for use with PPIs and H₂RAs without food restrictions1
Business Wire · 9m ago
Scott Bessent to address 'economic D-Day' on Iran this afternoon. Here's what to expect.
Yahoo Finance Video · 10m ago
Urinalysis Market worth $7.16 billion by 2031 - Exclusive Report by MarketsandMarkets™
PR Newswire · 10m ago
Modular Data Center Market Surges to $79.49 billion at a CAGR 17.7% by 2030 | Report by MarketsandMarkets™
GlobeNewswire · 10m ago
Trump threatens 50% Canada auto tariffs starting January 2027
Quartz · 10m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.